MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells

Luo,Dan; Dong,Xi‑Wen; Yan,Bing; Liu,Mei; Xue,Tian‑Hui; Liu,Hui; You,Jun‑Hao; Li,Fang; Wang,Zi‑Ling; Chen,Zhi‑Nan

doi:10.3892/mmr.2018.9676

MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells

Authors:
- Dan Luo
- Xi‑Wen Dong
- Bing Yan
- Mei Liu
- Tian‑Hui Xue
- Hui Liu
- Jun‑Hao You
- Fang Li
- Zi‑Ling Wang
- Zhi‑Nan Chen
View Affiliations

Affiliations: College of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, P.R. China, Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, Department of Oncology, Hainan Branch of General Hospital of PLA, Sanya, Hainan 572013, P.R. China
Published online on: November 20, 2018 https://doi.org/10.3892/mmr.2018.9676
Pages: 213-220
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Natural killer (NK) cells recognize stress‑activated NK group 2, member D (NKG2D) ligands in tumors. In the present study, the expression levels of NKG2D ligands were examined in four lung cancer cell lines (A549, PLA801D, NCI‑H157 and NCI‑H520). In the A549 cells, the expression of MHC class I polypeptiderelated sequence (MIC)A/B and UL16 binding protein (ULBP)1 was weak, the expression of ULBP2 was typical, and neither ULBP3 nor ULBP4 were expressed. The mechanism underlying the regulatory effect of a cancer treatment agent on the expression of NKG2D ligands was investigated using the proteasome inhibitor MG132. Following treatment for 8 h with MG132, the transcription levels of MICB and ULBP1 were upregulated 10.62‑ and 11.09‑fold, respectively, and the expression levels of MICB and ULBP1 were increased by 68.18 and 23.65%, respectively. Notably, MICB exhibited significant time‑dependent change. MG132 increased the transcription of MICB by acting at a site in the 480‑bp MICB upstream promoter. The activity of the MICB promoter was upregulated 1.77‑fold following treatment with MG132. MG132 treatment improved the cytotoxicity of NK cells, which was partially blocked by an antibody targeting NKG2D, and more specifically the MICB molecule. The expression of MICB induced by MG132 was inhibited by KU‑55933 [ataxia telangiectasia mutated (ATM) kinase inhibitor], wortmannin (phosphoinositide 3 kinase inhibitor) and caffeine (ATM/ATM‑Rad3‑related inhibitor). The phosphorylation of checkpoint kinase 2 (Chk2), an event associated with DNA damage, was observed following treatment with MG132. These results indicated that MG132 selectively upregulates the expression of MICB in A549 cells, and increases the NKG2D‑mediated cytotoxicity of NK cells. The regulatory effect of MG132 may be associated with the activation of Chk2, an event associated with DNA damage. The combination of MG132 with NK cell immunotherapy may have a synergistic effect that improves the therapeutic effect of lung cancer treatment.

View Figures

View References

1	Bellora F, Castriconi R, Dondero A, Carrega P, Mantovani A, Ferlazzo G, Moretta A and Bottino C: Human NK cells and NK receptors. Immunol Lett. 161:168–173. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gasser S and Raulet DH: Activation and self-tolerance of natural killer cells. Immunol Rev. 214:130–142. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bae DS, Hwang YK and Lee JK: Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell Immunol. 276:122–127. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kruse PH, Matta J, Ugolini S and Vivier E: Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 92:221–229. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yin X, Lu X, Zhang X, Min Z, Xiao R, Mao Z and Zhang Q: Role of NKG2D in cytokine-induced killer cells against lung cancer. Oncol Lett. 13:3139–3143. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mayes K, Elsayed Z, Alhazmi A, Waters M, Alkhatib SG, Roberts M, Song C, Peterson K, Chan V, Ailaney N, et al: BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligand. Oncotarget. 8:64344–64357. 2017. View Article : Google Scholar : PubMed/NCBI
7	Borchers MT, Harris NL, Wesselkamper SC, Vitucci M and Cosman D: NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 291:L222–L231. 2006. View Article : Google Scholar : PubMed/NCBI
8	Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F and Coligan JE: The NKG2D receptor: Immunobiology and clinical implications. Immunol Res. 40:18–34. 2008. View Article : Google Scholar : PubMed/NCBI
9	Coudert JD and Held W: The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol. 16:333–343. 2006. View Article : Google Scholar : PubMed/NCBI
10	Champsaur M and Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 235:267–285. 2010. View Article : Google Scholar : PubMed/NCBI
11	Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichardi M, Hahn G, et al: Host immune system gene targeting by a viral miRNA. Science. 317:376–381. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 285:727–729. 1999. View Article : Google Scholar : PubMed/NCBI
13	Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A and Cippitelli M: Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol. 183:4385–4394. 2009. View Article : Google Scholar : PubMed/NCBI
14	Haque M, Ueda K, Nakano K, Hirata Y, Parravicini C, Corbellino M and Yamanishi K: Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. J Gen Virol. 82:1175–1180. 2001. View Article : Google Scholar : PubMed/NCBI
15	Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A and Weller M: RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64:7596–7603. 2004. View Article : Google Scholar : PubMed/NCBI
16	Nachmani D, Stern-Ginossar N, Sarid R and Mandelboim O: Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 5:376–385. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lanier LL: NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 3:575–582. 2015. View Article : Google Scholar : PubMed/NCBI
18	Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M and Mandelboim O: Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol. 9:1065–1073. 2008. View Article : Google Scholar : PubMed/NCBI
19	Morisaki T, Onishi H and Katano M: Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res. 32:2241–2247. 2012.PubMed/NCBI
20	Tallerico R, Todaro M, Di FS, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN and La Rocca R: Human NK cells selective targeting of colon cancer-initiating cells: A role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 190:2381–2390. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL and Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 285:730–732. 1999. View Article : Google Scholar : PubMed/NCBI
22	Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ and Lutz CT: Proteasome regulation of ULBP1 transcription. J Immunol. 182:6600–6609. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother. 58:1275–1285. 2009. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE and Chapoval AI: Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 116:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
26	Singh NP, Mccoy MT, Tice RR and Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 175:184–191. 1988. View Article : Google Scholar : PubMed/NCBI
27	Tang KF, Ren H, Cao J, Zeng GL, Xie J, Chen M, Wang L and He CX: Decreased dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol. 182:233–239. 2008. View Article : Google Scholar : PubMed/NCBI
28	Venkataraman GM, Suciu D, Groh V, Boss JM and Spies T: Promoter region architecture and transcriptional regulation of the genes for the MHC class I-Related chain a and b ligands of NKG2D. J Immunol. 178:961–969. 2007. View Article : Google Scholar : PubMed/NCBI
29	Bartek J, Bartkova J and Lukas J: DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 26:7773–7779. 2007. View Article : Google Scholar : PubMed/NCBI
30	Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436:1186–1190. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ljunggren HG and Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
32	Liu J, Shen W, Tang Y, Zhou J, Li M, Zhu W, Yang H, Wu J, Zhang S and Cao J: Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells. Tumour Biol. 35:7531–7539. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhang L, Tang H, Kou Y, Li R, Zheng Y, Wang Q, Zhou X and Jin L: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J Cancer Res Clin Oncol. 139:1105–1115. 2013. View Article : Google Scholar : PubMed/NCBI
34	Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J and Hofmann TG: Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol. 10:812–824. 2008. View Article : Google Scholar : PubMed/NCBI